EMG
VNDA icon

Ellington Management Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Ellington Management Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-28,400
Closed -$237K – 501
2016
Q1 		$237K Buy
+28,400
New +$233K 0.1% 309
2015
Q3 		– Sell
-10,281
Closed -$130K – 914
2015
Q2 		$130K Buy
+10,281
New +$111K 0.03% 635
2015
Q1 		– Sell
-10,900
Closed -$156K – 827
2014
Q4 		$156K Buy
+10,900
New +$129K 0.05% 493
2014
Q2 		– Sell
-16,200
Closed -$263K – 670
2014
Q1 		$263K Buy
16,200
+1,000
+7% +$14.2K 0.08% 418
2013
Q4 		$189K Buy
+15,200
New +$153K 0.07% 472
2013
Q3 		– Sell
-117,400
Closed -$949K – 981
2013
Q2 		$949K Buy
+117,400
New +$791K 0.18% 121

Other funds holding VNDA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ellington Management Group's VNDA Position: Q2 2016 in Review

Ellington Management Group sold out of Vanda Pharmaceuticals (VNDA) in Q2 2016, closing a stake of 28,400 shares — an estimated $237K sold.

Ellington Management Group first reported a position in VNDA in Q2 2013 and held it in 6 quarters. The position peaked at $949K in Q2 2013. 115 funds tracked by Wall St. Rank hold VNDA as of Q2 2016.

  • Ellington Management Group reported no remaining Vanda Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Ellington Management Group sold 28,400 Vanda Pharmaceuticals shares in Q2 2016, an estimated $237K.
  • Ellington Management Group first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • Ellington Management Group's Vanda Pharmaceuticals position peaked at $949K in Q2 2013.
  • 115 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2016.

Based on Ellington Management Group's 13F filing for Q2 2016, filed 15 Aug 2016.